Provided by Tiger Trade Technology Pte. Ltd.

AbCellera Biologics

3.16
+0.380013.67%
Post-market: 3.210.0500+1.58%19:52 EST
Volume:5.40M
Turnover:16.39M
Market Cap:945.90M
PE:-5.48
High:3.17
Open:2.94
Low:2.88
Close:2.78
52wk High:6.52
52wk Low:1.89
Shares:299.34M
Float Shares:202.75M
Volume Ratio:0.82
T/O Rate:2.66%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5768
EPS(LYR):-0.5533
ROE:-16.81%
ROA:-10.43%
PB:0.98
PE(LYR):-5.71

Loading ...

AbCellera Advances ABCL635 Menopause Candidate As Shares Trade Below Targets

Simply Wall St.
·
Jan 30

Press Release: AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

Dow Jones
·
Jan 23

Abcellera Biologics Inc. to Announce Full Year 2025 Financial Results

Reuters
·
Jan 23

AbCellera Biologics Showcases Progress in Antibody Drug Development and Clinical Pipeline

Reuters
·
Jan 15

AbCellera Doses First Patients in Phase 2 Trial of Menopause Drug Candidate

MT Newswires Live
·
Jan 12

AbCellera doses first patients in Phase 2 portion of ABCL635 trial

TIPRANKS
·
Jan 12

BUZZ-AbCellera rises as it starts mid-stage trial for menopause drug

Reuters
·
Jan 12

AbCellera Begins Phase 2 Trial of ABCL635 for Menopausal Vasomotor Symptoms

Reuters
·
Jan 12

Abcellera Announces First Patients Dosed in Phase 2 Portion of Its Phase 1/2 Clinical Trial of Abcl635 for the Treatment of Vasomotor Symptoms Due to Menopause

THOMSON REUTERS
·
Jan 12

Abcellera Biologics Inc - Anticipates Top-Line Results in Q3 2026

THOMSON REUTERS
·
Jan 12

AbCellera Biologics Inc. Files Initial Statement of Beneficial Ownership for Director Stephen Quake

Reuters
·
Dec 20, 2025

Sector Update: Health Care Stocks Rise Late Afternoon

MT Newswires Live
·
Dec 19, 2025

AbCellera Biologics Says Bruker to Pay $36 Million Upfront in Patent Litigation Settlement

MT Newswires Live
·
Dec 18, 2025

BRIEF-Abcellera And Bruker Reach Global Settlement Of Patent Litigation

Reuters
·
Dec 18, 2025

Abcellera Biologics Inc - Bruker to Pay Abcellera $36 Mln Upfront and Future Royalties

THOMSON REUTERS
·
Dec 18, 2025

Abcellera and Bruker Reach Global Settlement of Patent Litigation

THOMSON REUTERS
·
Dec 18, 2025

AbCellera to Present at J.P. Morgan Healthcare Conference

Reuters
·
Dec 09, 2025

Assessing AbCellera Biologics (ABCL) Valuation as It Shifts Toward Proprietary Clinical Assets and Phase 1 Trials

Simply Wall St.
·
Dec 06, 2025

Director John S. Montalbano Reports Acquisition of AbCellera Biologics Common Shares

Reuters
·
Nov 27, 2025

Assessing AbCellera Biologics (NasdaqGS:ABCL) Valuation After New Facility Launch and Pipeline Progress

Simply Wall St.
·
Nov 26, 2025